But with the combination of CTLA4 inhibitors, the myocarditis has tripled to 1.33% (32/2,412 patients) (94.6% cases in this study received PD-1/PD-L1 antibodies) (Salem et al., 2018). The gene discussed is PDCD1; the disease is myocarditis.